Oral Dexmedetomidine effect on pain management in pediatric ALL patients under blood sampling: A randomized, double blind, clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190804044429N11

Enrollment

Registered

2024-06-05

Start date

2024-05-21

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia. Acute lymphoblastic leukemia

Interventions

Intervention 1: Intervention group: Half of the patients will receive oral dexmedetomidine in combination with 5 milliliter of apple juice before blood sampling. Intervention 2: Control group: Half o

Eligibility

Sex/Gender

All

Age

2 Years to 16 Years

Inclusion criteria

Inclusion criteria: Children from 2 to 16 years old ALL patients In the phase of maintenance treatment according to the COG protocol ASA score 1-2 Admitted to the hematology and oncology department of Bou Ali Sina Hospital Candidate for blood sampling

Exclusion criteria

Exclusion criteria: Congenital heart disease Mentally disabled Use of psychiatric medications Taking beta blockers History of arrhythmias Recent respiratory infection

Design outcomes

Primary

Measure	Time frame
Reducing the intensity of pain and restlessness in children with ALL. Timepoint: During the period of receiving maintenance treatment. Method of measurement: numerical rating scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMonireh Ghazaeian

Mazandaran University of Medical Sciences

Ghazaeianm@gmail.com+98 11 3334 3989

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026